ArticleFrontiers in oncology2026
RBM3-associated germline variants and their functional role in gastric cancer susceptibility and progression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is the fifth most commonly diagnosed malignancy and the fourth leading cause of cancer-related mortality worldwide. RNA-binding motif protein 3 (RBM3) has been associated as a prognostic marker in several cancers; however, its genetic contribution and functional role in gastric cancer remain unclear. Methods: Genome-wide association study (GWAS) data was integrated with experimental validation to investigate the role of RBM3 in GC. RBM3-associated expression quantitative trait loci (eQTLs) were identified from a GWAS of 3,301 individuals and evaluated for their association with GC risk using a large-scale GWAS comprising 456,348 individuals. Colocalization analysis was performed using stomach tissue eQTL data. RBM3 expression was assessed in 60 paired GC and adjacent normal tissues and in multiple GC cell lines. Functional effects of RBM3 modulation were examined through proliferation, colony formation, migration, invasion, and xenograft assays. Results: Several independent variants within the RBM3 locus showed a consistent protective association with GC risk and were linked to RBM3 expression regulation. RBM3 expression was significantly reduced in GC tissues compared with adjacent normal tissues (P < 0.001). Low RBM3 expression correlated with advanced tumor stage (III-IV), lymph node and distant metastasis, and larger tumor size. Functionally, RBM3 overexpression inhibited GC cell proliferation, clonogenicity, migration, and invasion Conclusion: Our findings demonstrate that RBM3 acts as a genetically supported tumor suppressor in gastric cancer. RBM3-associated germline variants contribute to GC susceptibility, and RBM3 downregulation promotes aggressive tumor behavior. RBM3 therefore represents a promising biomarker and potential therapeutic target in gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.